MedTrace Logo

Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery

NCT03956017 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2021-08-31

No results posted yet for this study

Summary

N Terminal (NT)-Pro b-type natriuretic peptide (BNP) levels provide incremental value in perioperative risk assessment prior to major non-cardiac surgery. The investigators will test whether pharmacologically lowering this biomarker with daily administration of CoQ10 for 3 days prior to elective vascular surgery will reduce adverse outcomes following the operation.

Conditions

  • Myocardial Injury

Interventions

DRUG

Ubiquinone

Take oral tablets as directed (2x200 mg for 3 days prior to surgery)

DRUG

Placebo

Take oral tablets as directed (2x200 mg for 3 days prior to surgery)

Sponsors & Collaborators

  • Minneapolis Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • EDWARD MCFALLS, MD · SITE PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-05
Primary Completion
2022-08-04
Completion
2022-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956017 on ClinicalTrials.gov